Effera® - Clinical Research Data Summary
effera® Recombinant Human Lactoferrin (rhLF)
effera® is a clinically studied ingredient that will be used in an upcoming Silver Fern™ Brand product.
Introduction
effera® is a recombinant human lactoferrin (rhLF) ingredient designed to replicate the structure and function of native human lactoferrin — a bioactive, iron-binding glycoprotein naturally present in colostrum, mature milk, and mucosal secretions throughout the body. Unlike bovine lactoferrin, effera® has an identical amino acid sequence to human lactoferrin and demonstrates similar digestive stability and bioactivity.*
Lactoferrin is involved in multiple physiological processes related to gut and immune health. It binds iron within the intestinal environment, helping to support a balanced microbial ecosystem, promotes the growth of beneficial bacteria such as Bifidobacterium, supports intestinal barrier function, and contributes to normal immune system activity.*
Across preclinical toxicology studies, allergenicity assessments, and randomized controlled human trials, effera® has been shown to have a favorable safety profile and good tolerability, with no observed evidence of treatment-emergent anti-human lactoferrin antibodies — supporting its compatibility with normal immune recognition.*
These are the studies for effera®, followed by public domain reviews on bovine lactoferrin to show its many functions. Below, we provided a summary of each key data for each study, along with a link to the complete clinical research.
- Summary of Study 1 – Full Study: https://journals.sagepub.com/doi/epub/10.1177/10915818241293723
- Summary of Study 2 – Full Study: https://www.medrxiv.org/content/10.64898/2025.12.31.25343278v1
- Summary of Study 3 – Full Study: https://www.sciencedirect.com/science/article/pii/S027869152400293X
- Summary of Study 4 – Full Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC10825996/
- Summary of Study 5 – Full Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC9104648/
Ingredient Manufacturer Link: https://www.myhelaina.com/effera
Study 1 Summary
Complete Study Information: https://journals.sagepub.com/doi/epub/10.1177/10915818241293723
A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults
Peterson, R.D. et al. International Journal of Toxicology. 2025. 44(1):12–28.
This randomized, double-blind, active-controlled clinical trial evaluated the safety, tolerability, and immune response to recombinant human lactoferrin (effera®) when consumed orally by 66 healthy adults (ages 18–45) over 28 days with a 56-day follow-up (84 days total). A parallel observational arm of 24 non-supplemented adults provided natural antibody variability reference data.
Study Design Highlights
- Study design: Randomized, double-blind, active-controlled
- Participants: 66 healthy adults (ages 18–45)
- Groups: 3.4 g/day rhLF (high dose, 10x margin), 0.34 g/day rhLF (low dose, approximating intended use), 3.4 g/day bovine lactoferrin (active control)
- Duration: 28 days supplementation + 56-day follow-up (84 days total)
- Primary outcome: Changes in anti-lactoferrin antibody levels
- Parallel arm: 24 non-supplemented adults (12 weeks) for natural antibody variability reference
Key Findings (What the Study Showed)
1. Immune Compatibility
Participants consuming recombinant human lactoferrin showed no meaningful increases in anti-human lactoferrin antibody levels — values remained within the range of natural biological variability seen in the observational group. The bovine lactoferrin group showed increases in anti-bovine lactoferrin antibodies consistent with exposure to a non-human protein; these changes were not associated with adverse clinical outcomes.
2. Clinical Safety Markers
Across all timepoints (Days 28, 56, and 84), no clinically meaningful changes were observed in hs-CRP, iron status markers, hemoglobin or hematocrit, comprehensive metabolic panel, or complete blood count. Iron-related adverse events were infrequent, mild, and occurred in participants with abnormal baseline values.
3. Tolerability
- No product-related serious adverse events
- No dose-dependent trends observed
- No product-related discontinuations
- Overall adverse event rates comparable across groups
- Compliance exceeded 93% in all groups
Benefits of effera® Demonstrated by This Study
Based directly on the clinical outcomes, effera® was shown to:
✓ Demonstrate no meaningful increases in anti-human lactoferrin antibodies vs. natural variability range
✓ Demonstrate immune compatibility profile distinctly different from bovine lactoferrin
✓ Maintain favorable clinical safety markers across all timepoints over 84 days
✓ Be well tolerated at both studied doses including 10x above intended use
✓ Achieve >93% compliance with no product-related discontinuations
Why This Study Matters
This study provides the core safety and immune compatibility evidence for effera® as an orally consumed dietary ingredient — demonstrating that recombinant human lactoferrin does not elicit unexpected immune responses, with a profile consistent with a human-identical dietary protein.*
Reference Link: https://journals.sagepub.com/doi/epub/10.1177/10915818241293723
Study 2 Summary
Complete Study Information: https://www.medrxiv.org/content/10.64898/2025.12.31.25343278v1
Safety, Tolerability, and Immunogenicity of Orally Administered Recombinant Human Lactoferrin in Healthy Adults: A Randomized, Double-Blind, Controlled Trial
medRxiv Preprint. 2025. doi: 10.1101/2025.12.31.25343278.
This randomized, double-blind, active-controlled clinical trial evaluated the safety, tolerability, and immune response to orally administered recombinant human lactoferrin in healthy adult men and women over 28 days with extended follow-up, including a non-supplemented observational cohort for natural antibody variability reference.
Key Findings (What the Study Showed)
- No meaningful increases in anti-human lactoferrin antibody levels — values remained within the range of natural variability identified in the observational cohort
- Bovine lactoferrin comparator demonstrated increases in anti-bovine antibodies consistent with non-human protein exposure (not associated with adverse outcomes)
- No product-related serious adverse events across all treatment groups
- No dose-related patterns observed
- No clinically meaningful changes in laboratory markers including iron-related parameters and inflammatory markers
- Adverse events generally mild and comparable between groups
- High adherence rates; no product-related discontinuations
Why This Study Matters
This preprint study independently replicates the key findings from Study 1, adding to the body of human clinical research evaluating oral recombinant human lactoferrin and further supporting its characterization as a dietary protein compatible with normal physiological processes.*
Reference Link: https://www.medrxiv.org/content/10.64898/2025.12.31.25343278v1
Study 3 Summary
Complete Study Information: https://www.sciencedirect.com/science/article/pii/S027869152400293X
A Review of the Safety Evidence on Recombinant Human Lactoferrin for Use as a Food Ingredient
Vishwanath-Deutsch, R. et al. Food and Chemical Toxicology. 2024. 189:114727.
This comprehensive narrative review published in Food and Chemical Toxicology evaluated the safety of orally ingested recombinant human lactoferrin produced in transgenic expression systems (rice, fungi, and cows), assessing toxicology, allergenicity, immunotoxicity, iron homeostasis, and ADME in the context of safety considerations for food use.
Key Findings (What the Review Showed)
1. Animal Toxicology
- No toxicologically relevant findings across multiple 28-day and 90-day oral studies in rats
- NOAEL established at the highest doses tested (up to 1000–2000 mg/kg/day in rats)
- Piglet studies: normal growth, no adverse hematologic changes, improved intestinal morphology (longer villi, deeper crypts)
- Safety consistent regardless of glycosylation profile or iron saturation state
2. Human Studies (15 trials reviewed)
- Populations ranging from healthy adults to vulnerable clinical populations
- Doses ranging from 1.25 g/day to 15 g/day; treatment durations up to 42 weeks
- Well tolerated across studies with no increase in serious adverse events vs. placebo
- No evidence of hematologic, renal, or hepatic toxicity; no dose-limiting toxicities
- No clinically meaningful changes in iron status
3. Allergenicity Risk
- No IgE binding observed in serum from individuals with milk or egg allergies
- No cross-reactive carbohydrate determinants of concern in cow-derived rhLF
- Rice-derived rhLF did not demonstrate basophil activation
- Existing literature supports low allergenic potential (formal allergenicity assessment remains a regulatory consideration)
4. ADME (Absorption, Distribution, Metabolism, Excretion)
- Partial resistance to gastric digestion; some intact lactoferrin detectable in GI tract
- Limited systemic bioavailability after oral ingestion; primarily local GI activity
- Rapid clearance if absorbed; distribution primarily to liver, spleen, kidneys
- No measurable increase in serum levels in Phase I study (Aspergillus-derived rhLF)
Why This Study Matters
This comprehensive safety review consolidates 20+ years of data and directly addresses prior regulatory concerns, concluding that general toxicology and tolerability data for recombinant human lactoferrin are strong and that allergenicity risk appears low. It also outlined the structured safety roadmap that led to the targeted immune studies in Studies 1 and 2.*
Reference Link: https://www.sciencedirect.com/science/article/pii/S027869152400293X
Study 4 Summary
Complete Study Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC10825996/
The Effectiveness of Oral Bovine Lactoferrin Compared to Iron Supplementation in Patients with Low Hemoglobin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Christofi, M.D. et al. BMC Nutrition. 2024. 10:20.
This PRISMA-guided systematic review and meta-analysis evaluated 19 randomized clinical trials (2,992 participants; 2006–2022) examining oral bovine lactoferrin (bLF) at 100–250 mg/day vs. iron supplementation (primarily ferrous sulfate) on hemoglobin levels and iron-related markers over 30–90 days across pregnant women, pediatric populations, and individuals with low hemoglobin. A 7-trial subset meta-analysis included 1,397 pregnant women.
Key Findings (What the Study Showed)
- Both iron supplementation and lactoferrin were associated with increases in hemoglobin levels over time across included studies
- Meta-analysis demonstrated a statistically significant difference favoring lactoferrin in the subset analysis (SMD: 0.81; 95% CI: 0.42–1.21)
- Longer study durations were associated with larger observed changes in hemoglobin
- Several studies reported changes in inflammatory markers (including IL-6) alongside iron-related improvements
- Multiple studies reported fewer gastrointestinal complaints in participants receiving lactoferrin vs. iron supplementation
- Higher adherence rates observed in some study populations with lactoferrin
Important Considerations
- Substantial variability across studies (I² = 95.8%)
- Some trials had methodological limitations
- Results were not uniform across all populations
- Findings should be interpreted within the context of study design differences and population variability
- This study evaluated bovine lactoferrin; effera® is recombinant human lactoferrin (human-identical, not bovine)
Why This Study Matters
This meta-analysis provides the largest aggregated dataset on oral lactoferrin and hemoglobin-related markers, highlighting lactoferrin's relationship with normal iron handling and tolerability relative to conventional iron supplementation. The tolerability findings are particularly relevant given the well-documented gastrointestinal discomfort associated with certain forms of iron supplementation.*
Reference Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC10825996/
Study 5 Summary
Complete Study Information: https://pmc.ncbi.nlm.nih.gov/articles/PMC9104648/
The Lactoferrin Phenomenon — A Multifunctional Protein
Kowalczyk, P. et al. Molecules. 2022. 27:2941.
This comprehensive narrative review published in Molecules summarized the biological properties of lactoferrin — a multifunctional iron-binding glycoprotein found in milk and human secretions — and its role in normal physiological processes across the lifespan.
Key Findings (What the Review Showed)
- Iron-binding: Lactoferrin is a high-affinity iron-binding protein (Fe³⁺) that plays a role in regulating iron availability within biological systems, supporting normal iron handling and utilization
- Antioxidant activity: Interacts with reactive compounds and supports antioxidant processes, helping to maintain cellular integrity under normal physiological conditions
- Immune system support: Involvement in normal immune activity including interactions with immune cells and signaling pathways associated with innate and adaptive responses
- Microbial balance: Involved in maintaining a balanced microbial environment in part through its ability to bind iron within the gut and mucosal surfaces
- Cellular and tissue support: Participates in processes related to cellular protection, tissue integrity, and normal cell signaling
- Lifespan relevance: Present from early development through aging and associated with physiological functions related to growth, development, and maintenance of normal biological systems
Important Considerations
This publication is a narrative review and does not present new experimental or clinical data. Many described mechanisms are based on preclinical or mechanistic studies. Observed effects may vary depending on dose, source, and population.
Why This Study Matters
This review establishes the comprehensive biological framework for lactoferrin as a multifunctional protein, providing mechanistic context for the safety and tolerability findings in Studies 1–3 and the iron-related clinical observations in Study 4.*
Reference Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC9104648/
Big-Picture Integration with Other Studies
- Study 1: Randomized, double-blind, active-controlled trial in 66 adults showing no meaningful increases in anti-human lactoferrin antibodies, no clinically meaningful safety marker changes, and >93% compliance at doses up to 3.4 g/day over 84 days.
- Study 2: Independently replicating Study 1 findings — consistent antibody profile within normal variability and good tolerability in healthy adults at studied intake levels.
- Study 3: Comprehensive safety review of 20+ years of data showing high NOAELs in animal models (up to 2000 mg/kg/day), favorable tolerability across 15 human studies (up to 15 g/day, up to 42 weeks), and low allergenicity potential.
- Study 4: Meta-analysis of 19 RCTs (2,992 participants) on bovine lactoferrin showing associations with hemoglobin-related markers and a favorable tolerability profile relative to conventional iron supplementation (SMD: 0.81 in subset analysis).
- Study 5: Comprehensive narrative review identifying lactoferrin as a multifunctional protein involved in iron regulation, antioxidant activity, immune function, microbial balance, and cellular health across multiple life stages.
effera® Ingredient Summary & Real-World Relevance
effera® is a recombinant human lactoferrin designed for oral consumption — structurally identical to endogenous human lactoferrin, a protein naturally present in human milk and mucosal secretions. As such, it reflects a protein that is already part of normal human biology.*
Across randomized controlled trials, preclinical toxicology studies, and comprehensive safety evaluations, recombinant human lactoferrin has demonstrated no meaningful increases in anti-human lactoferrin antibody levels, no consistent patterns of clinically meaningful adverse effects, high no-observed-adverse-effect levels in animal models, good tolerability in human studies, low likelihood of allergenic response, and limited systemic exposure after oral intake.*
The broader lactoferrin research base — including a 19-trial meta-analysis on bovine lactoferrin and comprehensive mechanistic reviews — highlights lactoferrin's role as a multifunctional protein involved in normal physiological processes related to iron balance, immune activity, microbial balance, and cellular health. Together, these findings support effera® as a well-characterized, human-identical protein ingredient for food, beverage, and dietary supplement applications.*
Ingredient Manufacturer Link: https://www.myhelaina.com/effera
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.